The Montreal biotech teaching antibodies to read the room - and act only where the disease actually is.
The mark reads like a command line and salutes like an antibody: two lime chevrons framing "ability_bio," the Y-shaped brackets a quiet nod to the molecule the whole company is built around.
Here is a problem that has quietly frustrated antibody drug developers for decades: the target you want to hit is almost never only on the cells you want to kill. A protein that is wildly overexpressed on a tumor is usually also sitting, in smaller quantities, on some perfectly innocent tissue you would rather not disturb. So the antibody does its job, binds its target, and also lands somewhere it shouldn't. Clinicians have a clinical name for this - on-target, off-tissue toxicity - which is a polite way of saying the drug works and also hurts you.
Ability Biotherapeutics, a Montreal company founded in 2023 and also known by its legal name Ability Biologics, has organized itself around a single, slightly audacious response to that problem: what if the antibody could tell where it was? Not bind harder, not bind more - but bind conditionally, sensing some feature of the local environment and only switching on when the coast is clear. In the company's own framing, simply "binding, blocking or agonizing a single receptor is not enough to achieve therapeutic impact." The pitch is antibodies with a little logic built in.
This is the part where a lot of biotech companies would hand-wave about artificial intelligence, and to be fair Ability does invoke AI - but it is unusually specific about what the AI is for. Designing an antibody that behaves like an if-then statement is genuinely hard. You are asking a protein to fold into a shape that binds one thing, and a second thing, and to modulate that binding based on pH or a metabolite gradient. The search space is enormous and mostly full of molecules that don't work. The company's bet is that the way through that space is data - a lot of it - plus a model that keeps learning.
That model is called AbiLeap, and it is the actual product here, in the sense that a pipeline of drug candidates is really just the output of the machine that designs them. AbiLeap combines what the company describes as massively parallel, continuously-learning AI with one of the largest databases of antibody-antigen interactions ever assembled - more than five years of discovery data, both proprietary and public. Out of that it generates fully-human, IgG-based multispecific antibodies with, the company says, exquisite selectivity, affinity and developability.
The word doing quiet work in that sentence is developability. It is one thing to computationally invent a molecule with perfect binding properties; it is another for that molecule to be manufacturable, stable, and not prone to the dozen failure modes that kill antibodies on the way to the clinic. A discovery engine that only optimizes for binding is a research toy. One that also optimizes for whether you can actually make the thing at scale is a company. Ability is trying to be the second kind.
If you want to understand why serious investors wrote serious checks into a two-year-old company, don't look at the molecules. Look at the database.
The fashionable story in drug discovery right now is that AI will design our medicines. The less fashionable, more accurate version is that a model is only as good as what it was trained on, and in biology good training data is scarce, expensive, and mostly locked inside companies. Ability's argument is that its edge is not the algorithm - algorithms travel - but the corpus of antibody-antigen interactions it has spent years assembling. That is the thing a competitor cannot simply download.
From that corpus AbiLeap produces antibodies with two tricks the company emphasizes. The first is multispecificity: a single molecule engineered to engage more than one target at once, for instance a tumor antigen and a T cell, so the immune system is redirected precisely to the cancer. The second is conditional activation - antibodies tuned to sense pH or metabolites in the cellular microenvironment, so they behave differently inside a tumor than in healthy tissue. Combine the two and you get what the company calls logic-gated therapeutics.
It is worth being honest about stage. These are, for now, discovery and preclinical assets - promising molecules, not proven drugs. The history of oncology is littered with elegant mechanisms that looked unbeatable on a slide and disappointed in a patient. What Ability has is a platform thesis and early candidates to test it. That is exactly what a seed-stage biotech is supposed to have, and the honest read is that the next few years of preclinical data will decide whether the thesis holds.
Still, the structure is appealing. A platform company gets many shots on goal from one engine. Each new candidate makes the database a little richer, which makes the next candidate a little better - the flywheel every AI company wants and few in biology actually have. If AbiLeap works even partially as advertised, Ability isn't a bet on one drug. It's a bet on a factory.
Every candidate carries the prefix "Leap" - a small tell that each one came out of the same machine that shares its name.
| Candidate | Stage | Target / Modality | Indication |
|---|---|---|---|
| Leap 1121 | Preclinical | First-in-class immune-cell depleter | Autoimmune & inflammatory skin disease |
| Leap 1009 | Discovery | Mesothelin × CD3 T cell engager, pH-sensitive | Solid tumors |
| Leap 1030 | Discovery | TROP2 × CD3 T cell engager, pH-sensitive | Solid tumors |
Leap 1009 and 1030 are classic bispecific T cell engagers - one arm grabs the tumor, the other grabs a T cell - with a twist: the pH sensitivity is meant to keep them quiet in healthy, neutral tissue and active only in the acidic microenvironment of a tumor.
"We're seeing a need for a new generation of antibodies and modalities as simply binding, blocking or agonizing a single receptor is not enough to achieve therapeutic impact."
The company was launched out of venture firm Amplitude Ventures around two co-founders, then built out a full C-suite unusually quickly for its age.
Previously a co-founder of Distributed Bio, one of the most prolific antibody-engineering shops of the last decade. Left to build a discovery engine with logic baked in.
Technology co-founder and the architect behind the AbiLeap platform and its continuously-learning approach to antibody design.
Leads business strategy and partnerships as Ability moves from platform-building toward candidate development and potential collaborations.
Also on the executive bench: a Chief Scientific Officer, Chief Medical Officer, Chief People Officer and an Executive Chairman - plus an advisory board that has included veterans of checkpoint-inhibitor drug development.
The syndicate is the tell. When a founding VC, a strategic CRO, a pension fund and a real-estate-turned-life-science investor all show up, they are each seeing a different reason to be there.
Ability came out of stealth, unveiling AbiLeap and closing an initial US$12M seed led by Amplitude Ventures, with Fonds de solidarité FTQ, Charles River Laboratories, Alexandria Venture Investments and Page One Ventures.
An extension round brought the seed to US$18M, adding Investissement Québec and Theodorus to the cap table to fund the generation of novel, highly-targeted immunomodulators.
Ability moved into Phase 2 of Inspire Bio Innovations - a redeveloped former Montréal chest hospital - with plans to triple headcount by 2028 as candidates approach preclinical readiness.
For patients, the promise is narrow but real: cancer and autoimmune therapies that hit their target with fewer of the collateral effects that make current treatments hard to tolerate. Conditional, logic-gated antibodies are one of the more credible routes to widening the therapeutic window - the gap between a dose that works and a dose that harms.
For the pharmaceutical industry, Ability is the kind of company you either partner with or compete against. A working discovery engine that reliably produces developable multispecifics is an asset larger companies would rather license than rebuild. That is the quiet optionality in a platform business: the pipeline can succeed on its own, or the engine can become someone else's supply chain.
For Montreal and Quebec, Ability is a data point in an argument the region has been making for a while - that it can anchor serious, AI-native life-science companies rather than export the talent. A globally recruited team choosing to build in a repurposed hospital in Montreal is, in its way, the whole thesis of a life-science cluster made concrete.
And for anyone watching the collision of AI and biology, Ability is a useful test case. The company has made a specific, falsifiable claim: that a proprietary data moat plus a learning model can systematically produce antibodies smart enough to know where they are. Over the next few years, the preclinical data will say whether that claim survives contact with biology. Either way, it is a clean experiment.
The logo styles the company as ability_bio in a monospace font flanked by two lime chevrons - Y-shaped brackets that double as a nod to the antibody molecule.
Every drug candidate is named "Leap," a small tribute to the AbiLeap engine that designed it. The machine signs its work.
Ability's home, Inspire Bio Innovations, is a redeveloped version of the former Montréal Chest Institute - a hospital reborn as a biotech hub.
CEO Giles Day previously helped build Distributed Bio, giving Ability a founder with a genuine track record in industrial-scale antibody engineering.
Interviews, press coverage and platform explainers - straight from the source.
Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.
Last updated: